YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
INmune Bio, Inc. Appointments strengthen rare-disease commercialization planning and strategic partnering capabilities as Ebstrocel™ advances toward potential commercialization BOCA RATON, Fla., Sept. 14, 2026 (GLOBE NEWSWIRE) -- INmune Bi…
Image source: The Motley Fool. DATE Thursday, Aug. 6, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Chief Executive Officer - David J. Moss Chief Scientific Officer - Mark William Lowdell Need a quote from a Motley Fool analyst? Email pr@fool.com…
Image source: The Motley Fool. DATE Thursday, Aug. 6, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Chief Executive Officer - David J. MossChief Scientific Officer - Mark William Lowdell Need a quote from a Motley Fool analyst? Email pr@fool.com…
INmune Bio, Inc. Q2 2026 Earnings Call Summary - Moby Strategic Execution and Platform De-risking Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick…
Key Points Interested in INmune Bio, Inc.? Here are five stocks we like better. Regulatory and manufacturing progress: INmune Bio plans to seek conditional U.K. approval for Ebstrocel in late 2026, followed by applications in Europe and th…
BOCA RATON, Fla., July 31, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announced that on July 30, 2026, it received a research an…
Management to host conference call and webcast at 4:30 pm ET on that day BOCA RATON, Fla, July 31, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immu…
Secures Global Framework for Composition-of-Matter and Method-of-Treatment Claims Covering Lead Program Ebstrocel for Epidermolysis Bullosa and Next-Generation Engineered Modalities Extending to 2045 BOCA RATON, Fla., July 01, 2026 (GLOBE…
Boca Raton, FL, May 15, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB), a clinical-stage biotechnology company developing therapies that target innate immune dysfunction, today announced that results from its Phase 2 MINDFuL trial…
Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, April 30, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company targeting…
Major earnings expected after the bell on Monday include * Virgin Galactic Holdings (SPCE [https://seekingalpha.com/symbol/SPCE]) * Anadarko Petroleum Corp. (APC [https://seekingalpha.com/symbol/APC]) * Sangamo Therapeutics (SGMO [https://…
* INmune Bio (INMB [https://seekingalpha.com/symbol/INMB]) is scheduled to announce FY earnings results on Monday, March 30th, after market close. * The consensus EPS Estimate is -$0.27 [https://seekingalpha.com/symbol/INMB/earnings/estima…
Quant rankings for the upcoming earnings calendar show strength concentrated in consumer discretionary and select industrial and health care names, while weakness is more pronounced across health care, technology, and parts of consumer-fac…
[Nest of Eggs] LindaJoHeilman As the calendar turns from March to April, a holiday-shortened week still delivers a diverse set of earnings with the potential to offer fresh directional cues. Consumer and brand momentum will be in focus wit…
Plenary Presentation Highlights How Aligning Inflammatory Biomarker Enrichment with Mechanism of Action Offers a Blueprint for Success in Alzheimer’s Drug Development Boca Raton, FL, March 19, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASD…
Clinical investigators from the trial to share real-world experience treating RDEB patients with CORDStrom and present new data from the MissionEB clinical study Boca Raton, FL, Feb. 19, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: IN…
INmune Bio (INMB) has formally submitted its pre-submission package for CORDStrom with the United Kingdom’s Medicines and Healthcare Products Regulatory Agency. This early engagement step is designed to solicit targeted scientific, regulat…
Boca Raton, FL, Dec. 05, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (“INmune” or the “Company”), a clinical-stage inflammation and immunology company, announces a recently published overview of future applications and researc…
Boca Raton, FL, Dec. 01, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage biotechnology company developing inflammation and immunology therapies targeting innate immune dysfunction, announces new neuroimaging data…
Boca Raton, FL, Nov. 18, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage inflammation and immunology company, today announces two presentations at the upcoming 18th Clinical Trials on Alzheimer’s Disease conferen…
A downtrend has been apparent in INmune Bio, Inc. (INMB) lately. While the stock has lost 11.9% over the past four weeks, it could witness a trend reversal as a hammer chart pattern was formed in its last trading session. This could mean t…
BOCA RATON, Fla., Oct. 30, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient’s innate immune system to fi…
Earnings Call Insights: INmune Bio (INMB) Q2 2025 MANAGEMENT VIEW * David J. Moss announced his appointment as Chief Executive Officer following the retirement of co-founder RJ Tesi, stating, "I'm honored to address you today as the new Ch…
Introduction & Market Context INmune Bio Inc (NASDAQ:INMB) presented its corporate strategy and clinical progress in August 2025, highlighting advances across its three immunomodulatory platforms. The biotech company, which focuses on harn…
BOCA RATON, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, toda…
Before the US market kicks off on Monday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers. [premarket] GAINERS TICKER CHANGE COMMENT PBM [https://www.chartmill.com/stock/quote/PBM/pro…
Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, July 31, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company, today ann…
Boca Raton, July 29, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) announced today that a video detailing the additional findings from the Phase 2 MINDFuL trial evaluating XPro™, a novel selective soluble TNF inhibitor, will be p…
Investing.com -- INmune Bio (NASDAQ:INMB) shares fell another 6% to about $2.17 on Tuesday after brokerages downgraded the stock, saying failure of the company’s experimental Alzheimer’s drug XPro in a mid‑stage trial sharply weakens its i…
Investing.com – U.S. stocks were higher after the close on Monday, as gains in the Telecoms, Financials and Technology sectors led shares higher. At the close in NYSE, the Dow Jones Industrial Average added 0.63% to hit a new 3-months high…
Boca Raton, Florida, June 30, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company, today announced that it has closed its registered direct offering, announced on Ju…
Investing.com - Raymond James downgraded INmune Bio Inc. (NASDAQ:INMB) from Outperform to Market Perform following disappointing Phase 2 trial results for the company’s XPro therapy in early Alzheimer’s disease. The stock has fallen over 1…
[Alzheimers Concept Horizontal] travellinglight/iStock via Getty Images Shares of INmune Bio (NASDAQ:INMB [https://seekingalpha.com/symbol/INMB]) dropped on Monday after the company did not achieve the main goal in a mid-stage trial for it…
In the Phase 2 MINDFuL trial of XPro™ in patients with early Alzheimer’s Disease (AD) with biomarkers of inflammation, the modified intent-to-treat (mITT) population (n=200) did not meet the primary cognitive endpoint (EMACC), however in a…
(RTTNews) - INmune Bio Inc. (INMB) is scheduled to host a conference call on Monday, June 30, 2025, beginning at 8:00 am EDT to present top-line data from its phase II trial, dubbed MINDFuL. MINDFuL is a phase II trial investigating XPro i…
[Trading charts background] da-kuk/E+ via Getty Images Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week. MOND…